|
Blow to Pipelines: Interchangeability Likely to Require Clinical Data
The FDA appears poised to require clinical trial data from drugmakers seeking interchangeability designations for biosimilars, a move that could shrink the number of products aiming to achieve the standard, drugmakers and legal experts say.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives